MIND Act of 2025
- Sponsor
- Sen. Schumer, Charles E. [D-NY]
- Committees
- Commerce, Science, and Transportation Committee (primary)
- Last action
- Sep 29, 2025
Bottom line
The MIND Act initiates a comprehensive federal effort to understand and regulate the collection, use, and transfer of neural and related data, aiming to balance innovation with privacy and prevent misuse by both the private sector and federal agencies.
What it actually does
This bill directs the Federal Trade Commission (FTC) to conduct a comprehensive study on the governance of neural data and other related data, including assessing existing laws, identifying gaps, and proposing a regulatory framework. It also mandates the Office of Science and Technology Policy (OSTP) and the Office of Management and Budget (OMB) to develop and issue binding guidance for federal agencies on the procurement and use of neurotechnology, with a subsequent prohibition on inconsistent use.
Proponents argue
Proponents argue that existing laws inadequately address the unique risks posed by neural data, which can be monetized and used to shape individual behavior and decision-making. They contend that strong protections are essential to safeguard privacy, prevent discrimination and exploitation, and ensure that innovation in neurotechnology proceeds with accountability and public trust, especially given the potential for cognitive manipulation and erosion of personal autonomy.
Opponents contend
While the bill text does not explicitly state opposition, potential critics from the neurotechnology industry might argue that the broad definitions and focus on risks could lead to overly restrictive regulations that stifle beneficial innovation and economic growth. Concerns could also be raised about the potential for regulatory uncertainty during the study period and the administrative burden of compliance.
The bill is concise and clearly structured, making it accessible for an informed reader to understand its directives and scope within a short timeframe.
Section 1
Short Title
This section establishes the official short title of the Act as the "Management of Individuals' Neural Data Act of 2025" or the "MIND Act of 2025." This provides a common, easily referenceable name for the legislation, simplifying public discourse and legislative tracking.
Supporters argue
Supporters argue that a clear and memorable short title helps in public discourse and legislative tracking, making the bill's purpose more accessible and understandable to a wider audience.
Critics contend
No specific opposition is typically raised against short title provisions as they are standard legislative practice and do not contain substantive policy directives.
Tradeoffs
None apparent for this specific provision, as it serves a purely administrative function.
Section 2
Sense of Congress on Neural Data Risks and Protections
This section outlines Congress's understanding of the risks associated with neural data, including its monetization, potential for behavioral shaping, and the lack of transparency in interconnected neurotechnology systems. It emphasizes the absence of comprehensive federal privacy standards, the risks to civil liberties and national security, and the necessity of strong protections to ensure responsible innovation and public trust.
Section 3
Definitions of Key Terms
This section defines critical terms for the Act, including 'artificial intelligence,' 'Commission' (FTC), 'Federal agency,' 'neural data' (information from central or peripheral nervous system activity via neurotechnology), and 'neurotechnology' (devices/systems accessing or altering the nervous system). Crucially, it also defines 'other related data' as biometric, physiological, or behavioral information that can infer cognitive, emotional, or psychological states, such as heart rate variability or eye-tracking patterns.
Section 4(a)-(b)
Federal Trade Commission Study and Report on Neural Data Governance
This provision directs the Federal Trade Commission (FTC) to conduct a comprehensive study on the governance of neural data and other related data. The study must assess existing laws, identify regulatory gaps, recommend best practices for privacy and data security, and propose a regulatory framework that balances innovation with risk mitigation. The FTC is required to consult with various federal agencies, industry, academia, and advocacy groups, and submit a detailed report to Congress within one year, which must also be publicly published.
Section 4(c)
Annual Updates to FTC Findings
This provision requires the FTC to publicly update its report findings annually, starting one year after the initial report submission. These updates must reflect evolving advancements in neurotechnology, new data use cases, associated risks, and assess whether additional reports or guidance are necessary to ensure continued privacy protection.
Section 4(d)
Authorization of Appropriations for FTC Study
This provision authorizes the appropriation of $10,000,000 for the purpose of carrying out the FTC study and related activities mandated under Section 4. This funding is intended to provide the necessary financial resources for the Commission to conduct its comprehensive research and reporting.
Section 5
Conditional Limitations on Federal Agency Use of Neural Data
This provision directs the Director of the Office of Science and Technology Policy (OSTP), in consultation with the FTC and OMB, to develop guidance within 180 days of the FTC report. This guidance will outline prohibited, permissible, and conditionally permitted uses of neurotechnology by federal agencies, including safeguards, transparency, purpose limitations, and opt-in consent. OMB will then issue binding implementation guidance to all federal agencies within 60 days. One year after OMB's guidance, federal agencies are prohibited from procuring or operating neurotechnology that processes neural data in a manner inconsistent with this guidance.
The definition of 'other related data' includes biometric, physiological, or behavioral information that does not directly measure neural activity but can be processed to infer cognitive, emotional, or psychological states. Examples include heart rate variability, eye-tracking patterns, voice analysis, and facial expression recognition.
Section 3(6) - Definition of 'other related data'
Why it matters:This is standard legislative practice for defining terms. However, the breadth of this specific definition is critical and could be seen as intentionally expansive to capture a wide array of emerging data types.
Case for: Proponents argue that including 'other related data' is essential to prevent circumvention of privacy protections. Technologies that infer mental states from indirect signals pose similar risks to direct neural data and must be covered to create a comprehensive regulatory framework.
Case against: Critics might argue that this definition is overly broad, potentially encompassing a vast array of common consumer data and technologies (e.g., smartwatches, fitness trackers) not directly related to brain activity, leading to unintended regulatory burdens on unrelated industries.
Estimated impact: Significantly expands the scope of the FTC study and potential future regulations beyond direct neurotechnology, impacting a wide range of consumer electronics and data analytics companies.
The FTC report is required to include recommendations for a framework that suggests 'prohibited use cases regardless of individual consent' for neural data and other related data.
Section 4(b)(4)(A)(iii) - Report Contents: Prohibited Use Cases
Why it matters:While part of a detailed list, the power to recommend prohibitions 'regardless of individual consent' is a significant policy lever. Its placement could be seen as standard detail or as a way to include a strong regulatory concept without drawing immediate prominent attention.
Case for: Proponents argue that certain uses of neural data are so inherently risky or invasive (e.g., cognitive manipulation, involuntary surveillance) that they should be prohibited outright, even if an individual were to consent, to protect fundamental human rights and societal well-being.
Case against: Critics might argue that blanket prohibitions, even with good intentions, could limit individual autonomy and prevent beneficial applications, particularly in medical or assistive contexts where individuals might willingly consent to data use for personal improvement or treatment.
Estimated impact: If adopted, this recommendation could lead to federal bans on specific applications of neurotechnology and data analytics, fundamentally altering market development and research directions.
The FTC report must include recommendations regarding applications of neural data and other related data in specific sectors or practices that raise concerns, such as employment, educational settings (especially for children/teens), insurance, financial services, neuromarketing, commercial surveillance, data brokers, law enforcement, and sectors amplifying addictive use.
Section 4(b)(7)(A) - Report Contents: Applications in Specific Areas
Why it matters:This is a standard way to ensure a comprehensive study, but the enumeration of these specific high-risk areas signals the broad regulatory intent and potential future impact across numerous industries.
Case for: Proponents argue that explicitly listing these sensitive sectors ensures the FTC focuses its attention on areas where the misuse of neural data could have the most profound and detrimental societal impacts, such as discrimination, manipulation, or exploitation of vulnerable populations.
Case against: Industry groups in these sectors might argue that singling them out pre-judges their practices or creates unnecessary alarm, potentially leading to disproportionate regulation that could hinder legitimate and beneficial uses of data within their operations.
Estimated impact: Future regulations stemming from these recommendations could significantly alter data collection, processing, and usage practices across a wide array of industries, impacting millions of individuals.
The prohibition on federal agencies procuring or operating neurotechnology inconsistent with OMB guidance takes effect one year after the date on which OMB issues that guidance.
Section 5(b)(2) - Effective Date of Prohibition
Why it matters:This is standard legislative drafting for phased implementation, allowing time for agencies to prepare. It's not evasive but highlights that the actual prohibition is not immediate.
Case for: Proponents argue that a delayed effective date is necessary to provide federal agencies sufficient time to understand and implement the new guidance, procure compliant technologies, or adjust their operations, ensuring a smooth transition without disrupting critical government functions.
Case against: Critics might argue that a one-year delay after guidance is too long, leaving a significant window during which federal agencies could continue to use neurotechnology in potentially problematic ways, undermining the urgency expressed in the Sense of Congress.
Estimated impact: Provides a multi-year lead time (FTC study + OSTP/OMB guidance + 1 year) before the federal agency prohibition becomes active, allowing for extensive preparation and adaptation.